Linifanib in Treating Patients With Advanced, Refractory Colorectal Cancer

PRIMARY OBJECTIVES: I. To achieve an overall response rate of 15% or more. SECONDARY OBJECTIVES: I. Determine progression free survival. II. Determine overall survival. III. Evaluate toxicity profile of ABT 869 (linifanib) in this patient population. OUTLINE: Patients receive Linifanib orally (PO) once daily (QD). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up at 30 days, every 3 months for 2 years, and then every 6 months for 3 years.